Live market news
Stocks
BHVN

Biohaven Ltd.

BHVNStockUnited States

See in Charts

Latest news on BHVNranked by Oyticker for market impact

45Impact
Positive29 Sept 2026 · 00:57 UTC · Global · Medium term
Biohaven's BHV-1530 ADC Data Selected for Oral Presentation at EORTC-NCI-AACR 2026
Biohaven announced selection of clinical data on BHV-1530, a FGFR3-targeted antibody-drug conjugate with proprietary topoisomerase I payload, for oral presentation at the 2026 EORTC-NCI-AACR Symposium. Oral presentation status typically signals competitive clinical progress in oncology.
BHVNBiotechnologyOncologyPharmaceuticals

SEC filings

What BHVN filed

All its filings

29 Oct 2026
Results announced (opens the document on sec.gov)8-K
29 Oct 2026
Quarterly report (opens the document on sec.gov)10-Q
22 Oct 2026
Investor communication (opens the document on sec.gov)8-K
15 Oct 2026
Material agreement (opens the document on sec.gov)8-K
Investor communication
9 Sept 2026
Other event (opens the document on sec.gov)8-K
26 Aug 2026
Material agreement (opens the document on sec.gov)8-K
Investor communication
10 Aug 2026
Results announced (opens the document on sec.gov)8-K
10 Aug 2026
Quarterly report (opens the document on sec.gov)10-Q
7 Aug 2026
Executive or director change (opens the document on sec.gov)8-K
9 Jul 2026
Executive or director change (opens the document on sec.gov)8-K
27 May 2026
Investor communication (opens the document on sec.gov)8-K

From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.

Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.

Latest news on BHVNranked by Oyticker for market impact

Biohaven's BHV-1530 ADC Data Selected for Oral Presentation at EORTC-NCI-AACR 2026

What BHVN filed